VALIDATION OF TRANSILLUMINATION AND THE NEVOSCOPE

Information

  • Research Project
  • 2869811
  • ApplicationId
    2869811
  • Core Project Number
    R41CA076759
  • Full Project Number
    1R41CA076759-01A2
  • Serial Number
    76759
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/1999 - 25 years ago
  • Project End Date
    6/30/2001 - 23 years ago
  • Program Officer Name
    TORRES-ANJEL, MANUEL J.
  • Budget Start Date
    7/1/1999 - 25 years ago
  • Budget End Date
    6/30/2001 - 23 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    6/11/1999 - 25 years ago
Organizations

VALIDATION OF TRANSILLUMINATION AND THE NEVOSCOPE

DESCRIPTION: The investigators propose to test the clinical utility of their trans-illumination device for the imaging and diagnostic discrimination of malignant from non-malignant pigmented skin lesions, as further described by their abstract: "Melanoma is a lethal skin cancer that has a very high cure rate if detected early. A prototype device for early detection of melanoma, called the Nevoscope, has been built by Tranlite. It produces transillumination and epiluminescence images of pigmented lesions that are similar to the oil based epiluminescence but without the need for oil or the glass face-plate and could be a major innovation for early detection of melanoma. "In Phase I we will show, by imaging 80 pigmented lesions with the nevoscope, the feasibility of improving the detection accuracy for dysplastic nevi and melanoma compared to visual examination of oil based epiluminescence. We will also test a new prototype of the Nevoscope using white light emitting diodes which will significantly lower the price of the device and make it useful in other areas of medicine. "In Phase II we will develop and test the LED based nevoscope device for early detection of melanoma and other medical applications of skin imaging. The commercial goal of Translite is to significantly lower the price of a hand-held Nevoscope device that can be easily afforded by most physicians." PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R41
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    TRANSLITE, LLC
  • Organization Department
  • Organization DUNS
  • Organization City
    SUGAR LAND
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    774783195
  • Organization District
    UNITED STATES